Drugs / Heat Stable Rotavirus (HSRV) Vaccine
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02728869 | Jun 2016 → Mar 2017 | Rotavirus infection | MSD Wellcome Trust Hilleman Laboratories Pvt. Ltd. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Heat Stable Rotavirus (HSRV) Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02728869 ↗ |
| Known as | heat-stable rotavirus vaccine | “Objectives: To assess the safety and reactogenicity of single oral dose of heat-stable rotavirus vaccine (HSRV) in healthy adults aged 18-45 years followed by assessment of...” PMID 31526218 ↗ Oct 2019 |
| Modality | Vaccine | “It is a lyophilized live attenuated pentavalent (G1-G4 and P1\[8\]) heat-stable rotavirus vaccine (HSRV)” NCT02728869 ↗ |
| Route | Oral | “single oral dose of heat-stable rotavirus vaccine (HSRV)” PMID 31526218 ↗ Oct 2019 |